Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Peripheral circulating myeloma cells accurately identify bone marrow MRD positivity in multiple myeloma patients receiving CAR T or autologous transplant

View Full Paper
Ask AI
Bookmark
Share

Authors

RTRahul ThakurTOTracey L. O’ConnorFKFrank Kuhr

Discussion

Loading...

Member takes

Overview

Observational analysis showed high concordance of CMMCs with MRD in multiple myeloma patients, suggesting CMMC monitoring is beneficial for timely intervention.

Key Points

  • CMMC enumeration identified MRD-positive bone marrow with a sensitivity of 89.3% and a specificity of 91.3%.
  • The study found a 90.2% concordance rate between CMMC detection and bone marrow MRD, with a Cohen's kappa coefficient of 0.79.
  • Assessment utilized next-generation sequencing for MRD analysis and CELLSEARCH platform for CMMC enumeration.
  • Incorporating CMMC monitoring may enable more frequent surveillance and early detection of MRD conversion.

Cite This Study

Thakur et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da97https://doi.org/10.1182/blood-2025-4075
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Kinetics of circulating multiple myeloma cells (CMMCs) in patients undergoing standard-of-care anti-BCMA chimeric antigen receptor T cell therapy for Relapsed/Refractory multiple myeloma2025 · 1 citations
  2. 2Liquid biopsy for non-invasive molecular characterization and measurable residual disease analysis in multiple myeloma2025
  3. 3Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high‐sensitivity detection of ctDNA by next‐generation sequencing2026 · 1 citations
  4. 4Novel method of minimal residual disease testing in myeloma: Liquid biopsies to enumerate and 3D telomere-profiling of circulating tumor cells2025 · 1 citations
  5. 5Disease burden by NGS in bone marrow and peripheral blood samples at baseline and after frontline therapy: Subgroup analysis of the advance randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)2025